Please go to the PowerPak homepage
and select a course.
Anemia Management in Lower-Risk Myelodysplastic Syndromes: Current and Emerging Treatment Options
This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Bristol Myers Squibb.
Registration & Dates for Activities
Tuesday, July 20, 2021
1:00 - 2:00 PM ET
Thursday, July 29, 2021
4:00 - 5:00 PM ET
Christopher Fausel, PharmD, MHA
Senior Pharmacist, Oncology Precision Genomics
Department of Pharmacy
Indiana University Simon Comprehensive Cancer Center
Dr. Fausel has disclosed that he has no actual or potential conflicts of interest in relation to this program.
The clinical reviewer, Lisa Holle, PharmD, has disclosed that she has served as a consultant for McGraw Hill Education and Postgraduate Healthcare Education; and has received honoraria from Pharmacy Times Continuing Education, Postgraduate Healthcare Education, AXIS Medical Education, HOPA, HMP CME and ISOPP.
Susanne Batesko, RN, BSN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credits: 1.0 hours (0.10 ceu)
Type of Activity: Application
Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 60 minutes
This accredited activity has been designed for oncology, managed care, and specialty pharmacists.
HOW TO OBTAIN CREDIT
Participants must 1) read the learning objectives and faculty disclosures; 2) attend and participate in the live webinar; and 3) complete the evaluation form directly after the event with a maximum of within 60 days of attending the live session. To answer the questions, click on your selected choice for each answer then proceed to the next question. Your credit will automatically uploaded to CPE Monitor.
To provide oncology, managed care, and specialty pharmacists enhanced knowledge on currently available and emerging options for anemia management in patients with lower-risk MDS to ensure appropriate access to treatment and enhanced pharmaceutical care to optimize outcomes.
At the conclusion of this program, the learner will be able to do the following:
- Describe the varying presentations and prognoses of myelodysplastic syndromes (MDS)
- Discuss current supportive care options for anemia in lower-risk MDS, including limitations of such therapies
- Explain new and emerging management options for anemia in lower-risk MDS.
- Formulate approaches to provide optimal management of patients with anemia in MDS
REQUIRED COMPUTER HARDWARE/SOFTWARE
Please ensure the computer system you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
- Peripherals: Computer speakers or headphones
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5
Disclosure of Unlabeled Use and Disclaimer
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, or Bristol Myers Squibb. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.
The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.